pmc logo image
Logo of gutGutCurrent TOCInstructions to authors
Journal List > Gut > v.48(2); Feb 2001

Formats:
Gut. 2001 February; 48(2): 163–167.
doi: 10.1136/gut.48.2.163.
PMCID: PMC1728200
Copyright notice
Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: a new mechanism
A Leite, A Sipahi, A Damiao, A Coelho, A Garcez, M Machado, C Buchpiguel, F Lopasso, M Lordello, C Agostinho, and A Laudanna
Department of Gastroenterology, University of São Paulo (USP) Medica1 School, São Paulo, Brazil. Email: azl/at/po.cwru.edu
Small right arrow pointing to: This article has been cited by other articles in PMC.
Abstract
BACKGROUND—The pathogenesis of non-steroidal anti-inflammatory drug (NSAID) enteropathy is complex. It involves uncoupling of mitochondrial oxidative phosphorylation which alters the intercellular junction and increases intestinal permeability with consequent intestinal damage. Metronidazole diminishes the inflammation induced by indomethacin but the mechanisms remain speculative. A direct effect on luminal bacteria has traditionally been thought to account for the protective effect of metronidazole. However, a protective effect of metronidazole on mitochondrial oxidative phosphorylation has never been tested.
AIMS—To assess the protective effect of metronidazole on mitochondrial uncoupling induced by indomethacin and also on the increased intestinal permeability and macroscopic damage.
MATERIAL AND METHODS—The protective effect of metronidazole was evaluated in rats given indomethacin; a macroscopic score was devised to quantify intestinal lesions, and intestinal permeability was measured by means of 51Cr-ethylenediaminetetraacetic acid. The protective effect of metronidazole against mitochondrial uncoupling induced by indomethacin was assessed using isolated coupled rat liver mitochondria obtained from rats pretreated with metronidazole or saline.
RESULTS—Metronidazole significantly reduced the macroscopic intestinal damage and increase in intestinal permeability induced by indomethacin; furthermore, at the mitochondrial level, it significantly reduced the increase in oxygen consumption in state 4 induced by indomethacin and caused less reduction of the respiratory control rate.
CONCLUSION—Our study confirmed the beneficial effects of metronidazole on intestinal damage and intestinal permeability, and demonstrated, for the first time, a direct protective effect of metronidazole on uncoupling of mitochondrial oxidative phosphorylation caused by NSAIDs.


Keywords: uncoupling agents; intestinal permeability; enteropathy; non-steroidal anti-inflammatory drugs; metronidazole; indomethacin; rats
Full Text
The Full Text of this article is available as a PDF (159K).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Geis GS, Stead H, Wallemark CB, Nicholson PA. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol Suppl. 1991 Mar;28:11–14. [PubMed]
  • Collins AJ, Davies J, Dixon SA. Contrasting presentation and findings between patients with rheumatic complaints taking nonsteroidal anti-inflammatory drugs and a general population referred for endoscopy. Br J Rheumatol. 1986 Feb;25(1):50–53. [PubMed]
  • Langman MJ. Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):640–646. [PubMed]
  • Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999 Sep;45(3):362–366. [PubMed]
  • Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, Delacey G, Gumpel MJ, Levi AJ. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology. 1987 Sep;93(3):480–489. [PubMed]
  • Rooney PJ, Jenkins RT, Smith KM, Coates G. 111Indium-labelled polymorphonuclear leucocyte scans in rheumatoid arthritis--an important clinical cause of false positive results. Br J Rheumatol. 1986 May;25(2):167–170. [PubMed]
  • Segal AW, Isenberg DA, Hajirousou V, Tolfree S, Clark J, Snaith ML. Preliminary evidence for gut involvement in the pathogenesis of rheumatoid arthritis? Br J Rheumatol. 1986 May;25(2):162–166. [PubMed]
  • Bjarnason I, Zanelli G, Prouse P, Smethurst P, Smith T, Levi S, Gumpel MJ, Levi AJ. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet. 1987 Sep 26;2(8561):711–714. [PubMed]
  • Morris AJ, Madhok R, Sturrock RD, Capell HA, MacKenzie JF. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet. 1991 Mar 2;337(8740):520–520. [PubMed]
  • Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992 Sep 10;327(11):749–754. [PubMed]
  • Morris AJ, Wasson LA, MacKenzie JF. Small bowel enteroscopy in undiagnosed gastrointestinal blood loss. Gut. 1992 Jul;33(7):887–889. [PubMed]
  • Madhok R, MacKenzie JA, Lee FD, Bruckner FE, Terry TR, Sturrock RD. Small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs for rheumatoid arthritis. Q J Med. 1986 Jan;58(225):53–58. [PubMed]
  • Collins AJ, Du Toit JA. Upper gastrointestinal findings and faecal occult blood in patients with rheumatic diseases taking nonsteroidal anti-inflammatory drugs. Br J Rheumatol. 1987 Aug;26(4):295–298. [PubMed]
  • Bjarnason I, Price AB, Zanelli G, Smethurst P, Burke M, Gumpel JM, Levi AJ. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. Gastroenterology. 1988 Apr;94(4):1070–1074. [PubMed]
  • Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993 Jun;104(6):1832–1847. [PubMed]
  • Huber T, Ruchti C, Halter F. Nonsteroidal antiinflammatory drug-induced colonic strictures: a case report. Gastroenterology. 1991 Apr;100(4):1119–1122. [PubMed]
  • Sukumar L. Recurrent small bowel obstruction associated with piroxicam. Br J Surg. 1987 Mar;74(3):186. [PubMed]
  • Hershfield NB. Endoscopic demonstration of non-steroidal anti-inflammatory drug-induced small intestinal strictures. Gastrointest Endosc. 1992 May–Jun;38(3):388–390. [PubMed]
  • Hall RI, Petty AH, Cobden I, Lendrum R. Enteritis and colitis associated with mefenamic acid. Br Med J (Clin Res Ed). 1983 Oct 22;287(6400):1182. [PubMed]
  • Banerjee AK. Enteropathy induced by non-steroidal anti-inflammatory drugs. BMJ. 1989 Jun 10;298(6687):1539–1540. [PubMed]
  • Tanner AR, Raghunath AS. Colonic inflammation and nonsteroidal anti-inflammatory drug administration. An assessment of the frequency of the problem. Digestion. 1988;41(2):116–120. [PubMed]
  • Clements D, Williams GT, Rhodes J. Colitis associated with ibuprofen. BMJ. 1990 Oct 27;301(6758):987. [PubMed]
  • Ravi S, Keat AC, Keat EC. Colitis caused by non-steroidal anti-inflammatory drugs. Postgrad Med J. 1986 Aug;62(730):773–776. [PubMed]
  • Schwartz HA. Lower gastrointestinal side effects of nonsteroidal antiinflammatory drugs. J Rheumatol. 1981 Nov–Dec;8(6):952–954. [PubMed]
  • Aabakken L, Osnes M. Non-steroidal anti-inflammatory drug-induced disease in the distal ileum and large bowel. Scand J Gastroenterol Suppl. 1989;163:48–55. [PubMed]
  • Kendall MJ, Nutter S, Hawkins CF. Xylose test: effect of aspirin and indomethacin. Br Med J. 1971 Mar 6;1(5748):533–536. [PubMed]
  • Coutrot S, Roland D, Barbier J, Van Der Marcq P, Alcalay M, Matuchansky C. Acute perforation of colonic diverticula associated with short-term indomethacin. Lancet. 1978 Nov 11;2(8098):1055–1056. [PubMed]
  • Campbell K, Steele RJ. Non-steroidal anti-inflammatory drugs and complicated diverticular disease: a case-control study. Br J Surg. 1991 Feb;78(2):190–191. [PubMed]
  • Wilson RG, Smith AN, Macintyre IM. Complications of diverticular disease and non-steroidal anti-inflammatory drugs: a prospective study. Br J Surg. 1990 Oct;77(10):1103–1104. [PubMed]
  • Campbell KL, De Beaux AC. Non-steroidal anti-inflammatory drugs and appendicitis in patients aged over 50 years. Br J Surg. 1992 Sep;79(9):967–968. [PubMed]
  • Finkelstein JA, Jamieson CG. An association between anti-inflammatory medication and internal pelvic fistulas. Dis Colon Rectum. 1987 Mar;30(3):168–170. [PubMed]
  • Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987 Oct;107(4):513–516. [PubMed]
  • Rampton DS, McNeil NI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut. 1983 Mar;24(3):187–189. [PubMed]
  • Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J. 1981 May;57(667):297–299. [PubMed]
  • Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJ, Bjarnason I. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol. 1995 Apr;30(4):289–299. [PubMed]
  • Mingatto FE, Santos AC, Uyemura SA, Jordani MC, Curti C. In vitro interaction of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: respiration and ATP synthesis. Arch Biochem Biophys. 1996 Oct 15;334(2):303–308. [PubMed]
  • Mahmud T, Rafi SS, Scott DL, Wrigglesworth JM, Bjarnason I. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum. 1996 Dec;39(12):1998–2003. [PubMed]
  • Somasundaram S, Rafi S, Jacob M, Sigthorsson G, Mahmud T, Sherwood R, Price AB, Macpherson A, Scott D, Wrigglesworth JM, Bjarnason I. Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Gut. 1997 May;40(5):608–613. [PubMed]
  • Brune K, Dietzel K, Nürnberg B, Schneider HT. Recent insight into the mechanism of gastrointestinal tract ulceration. Scand J Rheumatol Suppl. 1987;65:135–140. [PubMed]
  • Wax J, Clinger WA, Varner P, Bass P, Winder CV. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology. 1970 Jun;58(6):772–780. [PubMed]
  • Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. Effects of nonsteroidal antiinflammatory drugs on permeability of the small intestine in humans. J Rheumatol Suppl. 1992 Nov;36:83–84. [PubMed]
  • Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut. 1991 Mar;32(3):275–277. [PubMed]
  • Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology. 1997 Jan;112(1):109–117. [PubMed]
  • Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut. 1997 Sep;41(3):344–353. [PubMed]
  • Bjarnason I, Smethurst P, Levi AJ, Peters TJ. Intestinal permeability to 51Cr-EDTA in rats with experimentally induced enteropathy. Gut. 1985 Jun;26(6):579–585. [PubMed]
  • Aabakken L, Osnes M. 51Cr-ethylenediaminetetraacetic acid absorption test. Effects of naproxen, a non-steroidal, antiinflammatory drug. Scand J Gastroenterol. 1990 Sep;25(9):917–924. [PubMed]
  • Jenkins RT, Rooney PJ, Jones DB, Bienenstock J, Goodacre RL. Increased intestinal permeability in patients with rheumatoid arthritis: a side-effect of oral nonsteroidal anti-inflammatory drug therapy? Br J Rheumatol. 1987 Apr;26(2):103–107. [PubMed]
  • Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut. 1986 Nov;27(11):1292–1297. [PubMed]
  • Mahmud T, Somasundaram S, Sigthorsson G, Simpson RJ, Rafi S, Foster R, Tavares IA, Roseth A, Hutt AJ, Jacob M, Pacy J, Scott DL, Wrigglesworth JM, Bjarnason I. Enantiomers of flurbiprofen can distinguish key pathophysiological steps of NSAID enteropathy in the rat. Gut. 1998 Dec;43(6):775–782. [PubMed]
  • Brodie DA, Cook PG, Bauer BJ, Dagle GE. Indomethacin-induced intestinal lesions in the rat. Toxicol Appl Pharmacol. 1970 Nov;17(3):615–624. [PubMed]
  • Fang WF, Broughton A, Jacobson ED. Indomethacin-induced intestinal inflammation. Am J Dig Dis. 1977 Sep;22(9):749–760. [PubMed]
  • Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol. 1969 Feb;54(2):237–249. [PubMed]
  • Melarange R, Moore G, Blower PR, Coates ME, Ward FW, Ronaasen V. A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ-free rats. Aliment Pharmacol Ther. 1992 Feb;6(1):67–77. [PubMed]
  • Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins. 1977 Aug;14(2):333–341. [PubMed]
  • Satoh H, Guth PH, Grossman MI. Role of bacteria in gastric ulceration produced by indomethacin in the rat: cytoprotective action of antibiotics. Gastroenterology. 1983 Mar;84(3):483–489. [PubMed]
  • Wallace JL. Non-steroidal anti-inflammatory drug gastropathy and cytoprotection: pathogenesis and mechanisms re-examined. Scand J Gastroenterol Suppl. 1992;192:3–8. [PubMed]
  • Bjarnason I, Zanelli G, Smith T, Smethurst P, Price AB, Gumpel MJ, Levi AJ. The pathogenesis and consequence of non steroidal anti-inflammatory drug induced small intestinal inflammation in man. Scand J Rheumatol Suppl. 1987;64:55–62. [PubMed]
  • Bjarnason I, Macpherson A. The changing gastrointestinal side effect profile of non-steroidal anti-inflammatory drugs. A new approach for the prevention of a new problem. Scand J Gastroenterol Suppl. 1989;163:56–64. [PubMed]
  • Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989 Feb 9;320(6):365–376. [PubMed]
  • Malech HL, Gallin JI. Current concepts: immunology. Neutrophils in human diseases. N Engl J Med. 1987 Sep 10;317(11):687–694. [PubMed]
  • Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut. 1992 Sep;33(9):1204–1208. [PubMed]
  • Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation. 1993 Dec;17(6):641–662. [PubMed]
  • Davies GR, Wilkie ME, Rampton DS. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci. 1993 Mar;38(3):417–425. [PubMed]
  • Davies NM, Jamali F. Pharmacological protection of NSAID-induced intestinal permeability in the rat: effect of tempo and metronidazole as potential free radical scavengers. Hum Exp Toxicol. 1997 Jul;16(7):345–349. [PubMed]
  • LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed]
  • CHANCE B, WILLIAMS GR. A simple and rapid assay of oxidative phosphorylation. Nature. 1955 Jun 25;175(4469):1120–1121. [PubMed]
  • Aicardi G, Solaini G. Effects of niridazole and 5-nitroimidazoles on heart mitochondrial respiration. Biochem Pharmacol. 1982 Nov 15;31(22):3703–3705. [PubMed]
Figures and Tables
Figure 1
Figure 1
Figure 1  
Box and whisker plot showing median macroscopic score (horizontal line), 25th and 75th centiles (box), and range (whiskers) in the control (group 1, n=10), indomethacin (group 2, n=10), and indomethacin plus metronidazole (group 3, n=10) (more ...)
Figure 2
Figure 2
Figure 2  
Box and whisker plot showing median intestinal permeability (horizontal line), 25th and 75th centiles (box), and range (whiskers) in the control (group 1, n=17), indomethacin (group 2, n=16), and indomethacin plus metronidazole (group (more ...)
Figure 3
Figure 3
Figure 3  
Regression analysis of the effects of metronidazole on oxygen consumption in the basal state (S4) (values are µmol of oxygen/mg of protein).
Figure 4
Figure 4
Figure 4  
Regression analysis of the effects of metronidazole on respiratory control rate (RCR). Relation between consumption of oxygen with ADP (S3) and after it has been consumed (S4).
Articles from Gut are provided here courtesy of
BMJ Group

PubMed articles by these authors